The everolimusCexemestane combination is indicated in advanced breast cancer treatment and usually well tolerated. respectively). The 18F-FDG PET/CT could focus on pulmonary everolimus side effects, with a typical imaging pattern: alveolar-interstitial opacities associated with moderate uptake, more or less extensive, primarily influencing the lower lobes. Hardly ever, a pseudotumoral element may be recognized, related to… Continue reading The everolimusCexemestane combination is indicated in advanced breast cancer treatment and